Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maxine Tran

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
European Urology|August 1, 2025
Epidemiology of Renal Cancer: Incidence, Mortality, Survival, Genetic Predisposition, and Risk FactorsAlessandro Larcher, Riccardo Campi, Axel Bex, et al.
European Urology|February 4, 2025
Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitors and Subsequent Therapy for Renal Cell CarcinomaJens Bedke, Yasmin Abu Ghanem, Laurence Albiges, et al.
Applied Health Economics and Health Policy|July 22, 2022
Cost-Utility Analysis of Major System Change in Specialist Cancer Surgery in London, England, Using Linked Patient-Level Electronic Health Records and Difference-in-Differences AnalysisCaroline S Clarke, Mariya Melnychuk, Angus I G Ramsay, et al.
Trials|March 21, 2026
PARTIAL: study protocol for a clinical and cost-effectiveness of complex PARTIAL vs radical nephrectomy for clinically localised renal cell carcinoma randomised trialDiana Johnson, Ruth Thomas, Seonaidh Cotton, et al.
European Urology|March 21, 2025
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 UpdateAxel Bex, Yasmin Abu Ghanem, Laurence Albiges, et al.
European Urology|May 12, 2026
Management of Lymph Node-Positive Renal Cell Carcinoma: Updated Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines PanelUmberto Capitanio, Patricia Zondervan, Riccardo Campi, et al.
The Journal of Pathology|April 16, 2015
A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapyNelma Pertega-Gomes, Sergio Felisbino, Charlie E Massie, et al.
Plos One|February 3, 2012
Renal tubular HIF-2α expression requires VHL inactivation and causes fibrosis and cystsRuth E Schietke, Thomas Hackenbeck, Maxine Tran, et al.
BJR Case Reports|August 21, 2019
First-in-human <i>in vivo</i> non-invasive assessment of intra-tumoral metabolic heterogeneity in renal cell carcinomaMaxine Tran, Arash Latifoltojar, Joana B Neves, et al.
Nature Communications|September 25, 2023
Targetable NOTCH1 rearrangements in reninomaTaryn D Treger, John E G Lawrence, Nathaniel D Anderson, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
European Urology|August 1, 2025
Epidemiology of Renal Cancer: Incidence, Mortality, Survival, Genetic Predisposition, and Risk FactorsAlessandro Larcher, Riccardo Campi, Axel Bex, et al.
European Urology|February 4, 2025
Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitors and Subsequent Therapy for Renal Cell CarcinomaJens Bedke, Yasmin Abu Ghanem, Laurence Albiges, et al.
Applied Health Economics and Health Policy|July 22, 2022
Cost-Utility Analysis of Major System Change in Specialist Cancer Surgery in London, England, Using Linked Patient-Level Electronic Health Records and Difference-in-Differences AnalysisCaroline S Clarke, Mariya Melnychuk, Angus I G Ramsay, et al.
Trials|March 21, 2026
PARTIAL: study protocol for a clinical and cost-effectiveness of complex PARTIAL vs radical nephrectomy for clinically localised renal cell carcinoma randomised trialDiana Johnson, Ruth Thomas, Seonaidh Cotton, et al.
European Urology|March 21, 2025
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 UpdateAxel Bex, Yasmin Abu Ghanem, Laurence Albiges, et al.
European Urology|May 12, 2026
Management of Lymph Node-Positive Renal Cell Carcinoma: Updated Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines PanelUmberto Capitanio, Patricia Zondervan, Riccardo Campi, et al.
The Journal of Pathology|April 16, 2015
A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapyNelma Pertega-Gomes, Sergio Felisbino, Charlie E Massie, et al.
Plos One|February 3, 2012
Renal tubular HIF-2α expression requires VHL inactivation and causes fibrosis and cystsRuth E Schietke, Thomas Hackenbeck, Maxine Tran, et al.
BJR Case Reports|August 21, 2019
First-in-human <i>in vivo</i> non-invasive assessment of intra-tumoral metabolic heterogeneity in renal cell carcinomaMaxine Tran, Arash Latifoltojar, Joana B Neves, et al.
Nature Communications|September 25, 2023
Targetable NOTCH1 rearrangements in reninomaTaryn D Treger, John E G Lawrence, Nathaniel D Anderson, et al.
Pageof 3